Welcome to our dedicated page for Mei Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on Mei Pharma stock.
MEI Pharma Inc (MEIP) is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies, with an emphasis on oral treatments targeting specific cancer mechanisms. This page provides investors and industry observers with timely updates on the company’s clinical trials, regulatory milestones, financial performance, and strategic partnerships.
As a centralized resource for MEI Pharma news, this page aggregates press releases, earnings reports, and scientific updates related to its pipeline candidates including zandelisib (PI3K delta inhibitor) and ME-344 (mitochondrial inhibitor). Users can track progress across clinical development stages, from Phase 1 safety data to late-stage trial results.
The curated news collection serves investors seeking to monitor MEIP’s operational progress, partnership announcements with pharmaceutical companies, and presentations at major medical conferences. Content is organized chronologically and categorized for efficient navigation, ensuring stakeholders stay informed about developments impacting the company’s valuation and scientific trajectory.
Bookmark this page for direct access to MEI Pharma’s official communications, including FDA correspondence updates and analyses of trial data. Regular visitors gain a comprehensive view of the company’s position within the competitive oncology therapeutics sector without promotional bias.
MEI Pharma, Inc. (Nasdaq: MEIP) has announced a 1-for-20 reverse stock split, effective from April 17, 2023. This decision, approved by stockholders on January 5, 2023, aims to increase the per share trading price and meet Nasdaq's minimum bid price requirement for continued listing.
The split will reduce the number of outstanding shares from approximately 133.3 million to around 6.7 million. Fractional shares will not be issued; affected stockholders will receive cash equivalent to their fractional shares based on the closing price on April 14, 2023.
Computershare Trust Company will manage the transfer process. Changes to the CUSIP number will also take effect on the same date.
MEI Pharma and Infinity Pharmaceuticals have announced a merger agreement to create a combined company that will focus on advancing a diverse clinical-stage oncology pipeline. This includes three drug candidates: eganelisib, voruciclib, and ME-344, targeting various cancers. The merger is expected to be an all-stock transaction, with projected cash balance of approximately $100 million to fund operations through mid-2025. MEI shareholders are expected to own 58% and Infinity shareholders 42% of the new entity. The merger seeks to leverage combined expertise and resources to enhance therapeutic options for patients.
FAQ
What is the current stock price of Mei Pharma (MEIP)?
What is the market cap of Mei Pharma (MEIP)?
